How India Exports Meropenem to the World

In the United States, meropenem is approved for use as an injectable antibiotic. The brand name Merrem IV, manufactured by Pfizer, received FDA approval on June 21, 1996, for 500 mg and 1 g vials; however, these formulations have since been discontinued. Generic versions of meropenem are available, with multiple Abbreviated New Drug Applications (ANDAs) approved by the FDA, facilitating the entry of generic manufacturers into the market. As of January 2026, there are no specific import alerts related to meropenem from India, indicating compliance with FDA standards. Given that 15.5% of India's meropenem exports are directed to the U.S., it is imperative for Indian exporters to adhere to FDA regulations, including Good Manufacturing Practices (GMP) and proper labeling, to maintain market access.

In the European Union, meropenem is subject to marketing authorization by the European Medicines Agency (EMA). Manufacturers must comply with the EU's GMP requirements, which encompass stringent quality control and assurance measures. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and regulation of meropenem, ensuring that products meet safety, efficacy, and quality standards. Compliance with these regulatory frameworks is essential for Indian exporters targeting the EU and UK markets.

Meropenem is listed in the 20th edition (April 2017) of the WHO Model List of Essential Medicines, underscoring its importance in treating severe bacterial infections. The International Pharmacopoeia, published by WHO, provides standardized specifications for meropenem, serving as a reference for quality control. Additionally, meropenem is included in various national pharmacopoeias, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality standards across different regions.

In India, meropenem is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including meropenem, to ensure affordability. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of meropenem, ensuring compliance with national regulations and monitoring of pharmaceutical exports.

The primary patents for meropenem have expired, leading to increased generic competition globally. This has resulted in a more competitive market landscape, with multiple manufacturers producing generic versions of meropenem, thereby influencing pricing and market dynamics.

In August 2025, the NPPA revised the ceiling price for meropenem, reducing it by 5% to enhance affordability and accessibility. In October 2025, the EMA issued new guidelines on the manufacturing of carbapenem antibiotics, emphasizing stricter contamination control measures to prevent cross-contamination. In December 2025, the WHO updated the International Pharmacopoeia monograph for meropenem, incorporating new analytical methods to improve quality assurance. In January 2026, the FDA approved a new generic version of meropenem, increasing competition in the U.S. market. In February 2026, the CDSCO implemented a new online portal for the expedited processing of export NOCs for pharmaceuticals, streamlining the export process for manufacturers.

These developments reflect ongoing efforts by regulatory authorities to ensure the quality, safety, and affordability of meropenem, impacting both domestic and international markets.

India's pharmaceutical industry, including the production of Meropenem, heavily relies on Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) imported from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in this sector. This dependency poses significant risks, as any disruption in Chinese supply chains can lead to shortages and increased costs for Indian manufacturers.

To mitigate these risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, aiming to promote domestic manufacturing of critical KSMs, DIs, and APIs. As of September 2025, the scheme has led to the creation of manufacturing capacities for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore.

Our proprietary trade data indicates that the top five exporters of Meropenem from India account for 82.7% of the total export value, with SUN PHARMACEUTICAL INDUSTRIES LIMITED alone contributing 39.9%. This high supplier concentration increases the risk of supply chain disruptions, as any operational issues within these key companies could significantly impact global Meropenem availability.

The PLI Scheme for Pharmaceuticals, launched in March 2021, aims to enhance India's manufacturing capabilities and reduce import dependence. The scheme has a budgetary outlay of ₹15,000 crore and is expected to generate substantial employment and economic growth.

Geopolitical tensions and shipping disruptions in critical maritime routes, such as the Red Sea and the Strait of Hormuz, pose significant risks to the global pharmaceutical supply chain. Additionally, ongoing US-China trade tensions can impact the availability and cost of raw materials essential for Meropenem production. These factors can lead to delays, increased costs, and potential shortages in the supply chain.

• Diversify Supplier Base: Encourage the development of alternative suppliers for KSMs and APIs to reduce dependency on a single country or company.

• Enhance Domestic Production: Support initiatives like the PLI Scheme to boost local manufacturing capacities for critical pharmaceutical ingredients.

• Strengthen Supply Chain Resilience: Develop strategic reserves of essential raw materials and finished products to buffer against potential disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical events that could impact the pharmaceutical supply chain.

• Invest in Logistics Infrastructure: Improve domestic transportation and logistics networks to ensure efficient distribution of pharmaceutical products.

RISK_LEVEL: MEDIUM